{"entity":{"id":"nct06015048","kind":"trial","name":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of Pyrotinib and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT06015048 by Jiangsu HengRui Medicine Co., Ltd., with 364 participants planned, started 2023-08-11 and due to reach its primary completion in 2026-11. Interventions recorded: SHR-A1811 combined with Pyrotinib. and SHR-A1811 combined with other antitumor therapies.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06015048","url":"https://clinicaltrials.gov/study/NCT06015048"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pyrotinib","trastuzumab-rezetecan"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06015048","phase":"1/2","setting":"A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Efficacy of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":364,"outcomes":[]},"route":"/trials/nct06015048/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}